Pancreatic Endotherapy for Refractory Chronic Pancreatitis

Not Applicable

Completed

• Conditions: Pancreatic Duct Dilatation; Pancreatic Duct Stone; Pancreatic Duct Stricture

• Registration Number: NCT04232670
• Lead Sponsor: Oregon Health and Science University

Brief Summary

The purpose of this study is to evaluate whether endoscopic ultrasound (EUS) only versus EUS + endoscopic retrograde cholangiopancreatography (ERCP) with pancreatic endotherapy reduces pain in the treatment of chronic pancreatitis with pancreatic duct obstruction.

Detailed Description

This is a single center, pilot, sham-controlled clinical trial of ERCP with pancreatic endotherapy for pain secondary to chronic calcific pancreatitis with main pancreatic duct obstruction. Potential subjects will undergo a comprehensive baseline assessment including Quantitative Sensory Testing, to ensure enrollment criteria are met and baseline covariates are measured. Eligible subjects will complete a 14-day run-in period. If eligibility criteria persist, subjects will be randomized to diagnostic endoscopic ultrasound (EUS) + sham pancreatic endotherapy or diagnostic EUS + ERCP with pancreatic endotherapy as defined in the study protocol. Subjects will be followed by a blinded physician for the next 90 days, at which time the pilot trial outcomes will be measured. Regardless of outcomes, all subjects will be followed longitudinally for 12 months after randomization.

Study Timeline

• Study First Submitted: 2019-12-06
• Study First Submitted QC: 2020-01-16
• Study First Posted: 2020-01-18
• Study Start: 2020-10-09
• Primary Completion: 2024-06-30
• Study Completion: 2024-06-30
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-16
• Last Update Posted: 2024-11-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Average daily pain: Numeric Rating Scale (NRS)	Day -14 to Day 90	The average daily pain from the electronic diaries during the 14-day period preceding the 90-day assessment, compared to the average daily pain reported during the 14-day run-in. Clinical improvement will be defined by the change in the average pain score between these two intervals, and without the need for increased opioids or additional interventions/procedures. The investigators will employ the standardized 11-point Numeric Rating Scale (NRS) to capture average daily pain with the empirically-supported anchors of 0=No Pain and 10=Worst Pain Imaginable.

Secondary Outcome Measures

Name	Time	Method
Opioid Misuse	Baseline to Day 90	Using the instrument titled Current Opioid Misuse Measure (COMM), this will be evaluated by patient self-reported measures of risk for aberrant medication-related behavior in patients prescribed opioids for chronic pain.
Pain tolerance: Quantitative Sensory Testing	Baseline to Day 90	Using Quantitative Sensory Testing, assess thermal pain tolerance using 5 trials of cutaneous heat stimuli via the thermode of the Medoc TSA-II Neurosensory Analyzer.
Pain wind up	Baseline to Day 90	Using Quantitative Sensory Testing, assess thermal wind-up pain (3 trials) with the thermode delivering 20 brief suprathreshold thermal pulses at the rate of 1 pulse per 1.5 secs thereby selectively stimulating C-fibers (during the 3 trials of 30sec of repeated heat stimulation, subjects will indicate their level of pain severity using a dynamic visual analogue scale).
Pain Catastrophizing	Baseline to Day 90	The instrument titled Pain Catastrophizing Scale (PCS) used to assess pain catastrophizing will do the following: * Measure of negative cognitive-set brought to bear during painful experiences; * Predict functional impairment due to pain and pain-related depression
Quality of Life: Using the PROMIS 29 instrument	Baseline to Day 90	Using the PROMIS 29 instrument, quality of life will be assessed through this questionnaire evaluating anxiety, depression, fatigue, pain interference, physical function, sleep disturbance, ability to participate in social roles and activities, and a single pain intensity item.
Mechanical pain threshold	Baseline to Day 90	Using Quantitative Sensory Testing, assess the mechanical pain threshold using the IITC Life Sciences Digital Anesthesiometer applied to the distal phalange of the digiti minimi of the left hand (increased at rate of 10grams/sec; pressure recorded in grams).
Change from baseline in pain severity and functional impairment	Baseline to Day 90	At 90-days, change from baseline in functional impairment due to pain will be examined.; The instrument used is Brief Pain Inventory (BPI),; * Measures pain at its worst, least, average, and at time of evaluation; * Measures patient perception of effectiveness of current pain medications; * Measures functional impairment due to pain
Conditioned pain modulation	Baseline to Day 90	Using Quantitative Sensory Testing, assess conditioned pain modulation (3 trials) using mechanical pain thresholds assessed via the IITC Life Sciences Digital Anesthesiometer applied to the right trapezus (increased at rate of 10grams/sec; pressure recorded in grams) with and without simultaneous stimulation via the ATS thermode.

Trial Locations

Locations (2)

Oregon Health & Science University; 🇺🇸 Portland, Oregon, United States

Medical University of South Carolina; 🇺🇸 Charleston, South Carolina, United States